At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
TAK-954 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis
In Brief
A Phase 2 clinical trial evaluating TAK-954 and Placebo for Diabetic Gastroparesis and Idiopathic Gastroparesis. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Gastroparesis, Idiopathic Gastroparesis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartJan 2018
Primary CompletionJun 2019
Study CompletionJul 2019
TodayJul 2026
First PostedSep 13, 2017
Enrollment StartJan 2, 2018
Primary CompletionJun 7, 2019
Study CompletionJul 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.8 years ago
Interventions
TAK-954drug
TAK-954 IV infusion.
Placebodrug
TAK-954 placebo-matching IV infusion.